Stock LPCN LIPOCINE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Lipocine Inc.

Equities

LPCN

US53630X2036

Delayed Nasdaq
Other stock markets
 01:36:55 2024-06-18 pm EDT 		5-day change 1st Jan Change
10.5 USD -1.78% Intraday chart for Lipocine Inc. +34.27% +276.34%
Jun. 10 Lipocine Inc. Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late-Breaking Session at EASL Congress 2024 CI
May. 09 Earnings Flash (LPCN) LIPOCINE Reports Q1 Revenue $7.6M MT

Evolution of the average Target Price on Lipocine Inc.

Price target over the last 5 years

History of analyst recommendation changes

7cf.InPgAdn4T5AlOj28GrnDv-bl9RrDCV5tHSMMjrgWGYg.d0Ore6idIOIQdW-NQoquzKuJoyn6azoAL1FZ3vtELd0bJIxHjbcrqG1KUg~01b2fe56ab700446eadfecc94fc52bf8

Analyst Recommendations on Lipocine Inc.

LIPOCINE : HC Wainwright Adjusts Lipocine's Price Target to $3.50 From $2.50, Keeps Buy Rating MT
LIPOCINE : Cantor Fitzgerald Starts Lipocine at Overweight With $3 Price Target MT
LIPOCINE : Ladenburg Thalmann Adjusts Lipocine's Price Target to $2.50 From $3, Maintains Buy Rating MT
LIPOCINE : HC Wainwright Adjusts Price Target for Lipocine to $2.50 From $3, Maintains Buy Rating MT
LIPOCINE : Ladenburg Thalmann Upgrades Lipocine to Buy From Neutral, $3 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
10.69 USD
Average target price
33.19 USD
Spread / Average Target
+210.48%
High Price Target
33.19 USD
Spread / Highest target
+210.48%
Low Price Target
33.19 USD
Spread / Lowest Target
+210.48%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lipocine Inc.

HC Wainwright
Cantor Fitzgerald
Ladenburg Thalmann

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. LPCN Stock
  4. Consensus Lipocine Inc.